Safety and tolerability of the oral Xa inhibitor darexaban for secondary prevention after acute coronary syndromes

Tuesday, August 30, 2011 - 10:30 in Health & Medicine

A phase II dose-finding study has found that the new oral Factor Xa inhibitor darexaban was associated with a two to four-fold increase in bleeding when added to dual antiplatelet therapy in patients following an acute coronary syndrome.

Read the whole article on Physorg

More from Physorg

Latest Science Newsletter

Get the latest and most popular science news articles of the week in your Inbox! It's free!

Check out our next project, Biology.Net